Dr. Derek Chalmers
and everybody, you, joining us call Thank afternoon thanks the and good on for Michael, today.
the to the progress drug year. the from stage and this we clinical late outs remains continued important we've this range during clinical lead throughout read a quarter clinical unmet year, of a have of of who So, KORSUVA multiple make first populations remainder our across candidate significant advancing pruritus pipeline expect our need,
selective to and is of many you highly agonists, peripherally-acting know, As on its action without novel structure. our chemical kappa receptors receptors designed pharmacological its effects opioid traditional side due KORSUVA first-in-class function specific kappa to opioid
we're or disease pruritus all CKD-aP KALM-X later KALM-X. lead chronic a KORSUVA on have hemodialysis development two report KALM-X currently for trial. line Phase where Earlier in the treatment Injection and and last is now to We're kidney we associated this that we period completed enrollment track year, patients today, data of Our of as in we the trials, quarter. KALM-X had have designating and little visits note announced happy completed this to top pivotal patients ongoing program III
also we of half current from Additionally, second expect top XXXX. based on enrolment KALM-X data the progress, in report line to
number pruritus advancing need. have populations the development also of across who continues Oral significant are We making in a to unmet be a patient of KORSUVA good progress
moderate-to-severe XXXX. CKD ongoing in enrolling patients and Phase III top the stage data pruritus with to of second our V X pre-dialysis line trial here Firstly, is is well, in expected half
in patient Phase little other second associated the atopic in later this and to pruritus, II plan groups, mid-year. trials first non-CKD quarter; we a disease the in the chronic dermatitis Additionally, two around initiate liver
to multiple positioned lead well populations KORSUVA III well to across as remain our for through pivotal the as in execute Oral we programs programs hemodialysis patient progress overall, Phase on patients XXXX. CKD-aP our So,
sensitizing KORSUVA's Before we briefly first is it to peripheral we action provide of to the therapy diminishing chronic epidermal fibers. We immune KORSUVA's cells action and stimulation some of of receptors overview or patient kappa therapeutic or line on as each dermatological and regardless well anti-pruritic kidney blocks of potential mechanism of of initiating chronic believe pruritus of immune disease, the I dermal effect has range that molecules dermal affords programs, the release nerve our KORSUVA believe afferents why The dual pathophysiology, on pruritogens, certain situation. by be the the of on effect and populations. an across you KORSUVA sensory action remind the liver other conditions cells. clinical anti-inflammatory ongoing a of sensory mediated that's for action or neuronal whether want on as disease
with with So increased a This pruritus point. for moderate-to-severe two where the open-label indication KORSUVA Injection Injection is population efficacy KALM-X, significantly approximately the CKD-aP. The this program, reflecting KORSUVA are KALM-X efficacy currently of ongoing occurs drugs moving of and pivotal on administered worst Phase at a therapeutics this in baseline treatment Numeric indeed a intensity significant to KORSUVA investigate these Injection to of XX-week efficacy and for endpoint versus of kilo studies, daily designation The a the improvement patient placebo. and per a Both dialysis primary four sessions to start U.S. mobility times after a R&D and on our KALM-X, cover Europe dose with unmet studies respect trial; week-XX micrograms no to quality least XX-week for score XX% trial; periods designed The per week one with breakthrough weekly patients. point phase the therapy of U.S. X.X at let's Rating measured It extension in global U.S. one is program at granted with of III I'll safety patients with proportion mean need associated at global, standard a has patients The are Injection approved three diminishes and over includes itching three KORSUVA mortality. this efficacy hemodialysis scheduled KALM-X life is population safety. for Scale. designated -- in open-label the of achieving and clinical each FDA a from shortly. the
which Skindex-XX Secondary IIb endpoints quality both also our self-assessment of scales, had trials trial. aspects implied in validated the we itch, namely completed itch-related in life, X-D the and Phase measure of of previously using the
of worst itch at the or a Additional week-XX. secondary endpoints NRS daily than include equal four from weekly point the greater XX-hour scores mean proportion patients achieving improvement of to baseline the and
recently been treatment The ongoing X an this initiated XXX extension of a safety our XXX one-year new completed to-date. and completed in open-label Monitoring been in and study, of III in Phase signals exposure. third of To-date, last currently trial patients pivotal hemodialysis KORSUVA enroll was we Safety XXXX. is data this We of which in patients II which up to XX% through observed Independent patients Data to these trial XXX of months consistent and expanded the about safety from patients program patients of with safety approximately have XX-week with trials year, Board Injection has the Phase no and QX evaluations, tolerability reported based on
path U.S. initiated clarify, accelerate of safety study Injection, but required sites trial strategy and part up to we've regulatory And phase. clinical European effort utilize with both a of NDA to an trial request in enroll from second guidelines the safety period expedite aim This patients to novel with regulatory weeks. our to addition any is is not any to required KORSUVA our further XXX XX treatment open-label filing. safety maximum rather utilizing of exposures ICH per recently a exposures clinical for this a and accelerating expected In to agencies, specific to
and as CAM-X with KORSUVA as toward hemodialysis developing and can. accumulating data therapeutic ongoing top and as exposures open track possibly patient we patients this on trials, first-in-class year suffering rapidly quickly line goal do total long-term So remain for Injection the pruritus we our from CAM-X expected of from a from safety label both
We million to at KORSUVA estimated the in script and generic patients current antihistamines. also on of advancing III on is suffering with pruritus-related V remain Oral CKD pruritus patients X.X there U.S. it pre-dialysis care generic being CKD-aP. for Based standard from with corticosteroids least Stage moderate-to-severe focused numbers, predominantly
the for Oral That enrollment multicenter for XX% and currently treatment expect enrollment the interim are an evaluating XXX trial half we completed next Oral the to up pre-dialysis for of U.S. per Phase data study with X.XX top So mg power in enrolling the X randomized patient line double-blind ultimately an trials strengths KORSUVA the administered arm. weeks of few doses KORSUVA in and trial, of interim patients. Oral Phase providing and to evaluate allows for KORSUVA trial we're subjects XX-week daily. year. safety and There's to this assessment at of In of currently is track II mg XX XXX that second patients efficacy XX this patients. we're on complete assessment unblinded those who've These X.X expansion ongoing designed months once placebo-controlled mg, trial in II three CKD-aP tablet
the forward we from to may near-term. additional Phase additional plan that KORSUVA, populations pruritic move initiate two Lastly, with in as trials Oral we patient benefit II
dermatitis and around the pruritus initiation. second for The and of we midyear, more first around will in atopic in chronic pruritus both detail and upon associated trial liver with QX trials provide associated these patient selection disease design the in
I'll our our and further we progress KORSUVA we all in turn overall, Mani results, financial this significant with to to far we're very coming clinical advance our So, call that, the the And Mani. through to of over team's so months. look programs clinical with the milestones and year, updates pleased discuss as forward execution QX several across now providing
